Vanderbilt Clinical Trials

Roll-in Phase 1. Stage C HF (NYHA Class I-III) AND 1. Discharged from a HF hospitalization (all LVEFs) OR 2. Scheduled for appointment in HF clinic with a prior HF hospitalization within the past 12 months with LVEF >35% 2. Receives longitudinal HF care at VUMC main campus, including at least one visit prior to the roll-in phase Randomized Controlled Trial (beyond roll-in phase) 1. Willingness to continue and participate in the study visits and other study activities required for the RCT

Roll-in Phase 1. Unwilling or unable to provide informed consent for participation in the RCT 2. Those who require a walker or who cannot get out of a chair/bed on their own and walk independently (use of a cane is acceptable) 3. Age < 18 years 4. Stage D HF (advanced HF under evaluation for LVAD or transplant) 5. NYHA class IV symptoms 6. Congenital heart disease 7. Pregnant 8. Group 1 pulmonary hypertension 9. Moderate-severe or severe (3+ or greater) valvular heart disease 10. Physical or neuropsychiatric limitations that would prevent proficient use of the study tools and successful completion of the physical and quality of life assessments (e.g. blindness, dementia) 11. Planned surgery within 3 months 12. Pacemaker or internal cardioverter defibrillator placement or revision performed within past 1 month or planned within 3 months 13. Prior Cardiomems placement or planned in next 3 months 14. Planned discharge from hospital to hospice, assisted living, or inpatient rehabilitation facility (discharge to a senior facility permitted as long as they are considered Independent Living) 15. Treating provider or study team physician indicates that participation in the RCT would be unsafe 16. Participation in any ongoing randomized trial that has not completed follow-up Randomized Controlled Trial (beyond roll-in phase) 1. Not adherent to wearing the Actigraph activity tracker during the roll-in phase for a minimum of 4 (out of 7) compliant days (worn at least 10 hours/day). 2. Unable to complete the baseline study visit within 4 weeks of the completion of the roll-in actigraphy assessment.